GOG FOUNDATION® Transforming the standard of care

FACULTY DISCLOSURE INFORMATION

Symposium Optimizing Management of KRAS-Mutated Malignancies: Practical Approaches to Dosing, Monitoring, and Adverse Event Management

October, 17, 2026
Chicago, IL

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company *(**formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM ***An **"ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Slomovitz, MD	Brian	**Moderator Planner Speaker**	Merck; Daiichi; Incyte; AstraZeneca; Aadi; Corcept; AbbVie; BeOne; BioNTech; Genmab; Karyopharm; Eisai; GSK	Consultant
Speaker Disclosures				
Flint, NP	Michelle	**Speaker**	Corcept; Verastem	Speakers Bureau (Corcept) Advisory Board (Verastem)
Engbert	Holley	**Staff**	Nothing to disclose	
Rush	Heather	**Staff**	Nothing to disclose	
Shumaker	Kara	**Reviewer/Staff**	Nothing to disclose	
Small, MPH	Michelle N	**Reviewer/Staff**	Nothing to disclose	
Alvarez Secord, MD	Angeles	**Reviewer/Edu-Chair**	GSK; Gradalis; Genmab; Immunogen; Merck; TORL BioTherapeutics; Daiichi Sankyo; Mersana Therapeutics; AbbVie; CanariaBio Inc; Myriad; AstraZeneca; Corcept; Foundation Medicine; Gilead; Medical Advisory Board Project Nana; Steering Committee for Oval; AAOGF Board of Trustees; SGO Board; FWC Board; GOG Foundation Board) Intellectual Prop, Patents: (Royalties for Up to Date)	Research funds to Institution (GSK; Gradalis; Genmab; Immunogen; Merck; TORL BioTherapeutics; Daiichi Sankyo; Mersana Therapeutics; AbbVie; CanariaBio Inc; Myriad; AstraZeneca) Advisory Board with Honoraria (AbbVie; AstraZeneca; Corcept; Daiichi Sankyo; Foundation Medicine; GSK; Gilead; Merck) Other Relationships (Medical Advisory Board Project Nana; Steering Committee for Oval; AAOGF Board of

FACULTY DISCLOSURE INFORMATION

			Stock-Divested in June 2024 (Amgen; Johnson & Johnson)	Trustees; SGO Board; FWC Board; GOG Foundation Board) Intellectual Prop, Patents: (Royalties for Up to Date) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	**Edu-Co-Chair/ Reviewer**	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Zweizig, MD	Susan	**Reviewer/ GOG-F CME Working Cmte-Chair**	Nothing to disclose	
Blank, MD	Stephanie	**Reviewer**	American Board of Obstetrics and Gynecology; Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.	Leadership (American Board of Obstetrics and Gynecology) Research Funding (Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.)
Gien, MD	Lilian	**Reviewer**	Glaxo Smith Kline; Merck; Abbvie; AstraZeneca	Speaker Honoraria (Glaxo Smith Kline; Merck) Advisory Board (Abbvie; AstraZeneca)
Mutch, MD	David	**Reviewer**	Nothing to disclose	